Title |
Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction
|
---|---|
Published in |
Current Heart Failure Reports, August 2017
|
DOI | 10.1007/s11897-017-0358-4 |
Pubmed ID | |
Authors |
Jeremy Cypen, Tariq Ahmad, Jeffrey M. Testani, Adam D. DeVore |
Abstract |
The use of biomarkers in heart failure (HF) is a rapidly changing field. The purpose of this review is to assess the current evidence of the use of biomarkers for risk stratification in patients with HF with preserved ejection fraction (HFpEF). Despite differences in pathophysiology between HF with reduced ejection fraction and HFpEF, traditional HF biomarkers such as brain natriuretic peptide and troponin retain prognostic value in most HFpEF-specific populations. Biomarkers of key pathophysiologic components of HFpEF, such as myocardial fibrosis, remodeling, and systemic inflammation are also valuable prognostic markers. Further investigation into HF biomarkers may identify significant therapeutic targets for the treatment of HFpEF. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 14% |
Student > Master | 5 | 14% |
Student > Bachelor | 4 | 11% |
Other | 3 | 9% |
Student > Doctoral Student | 2 | 6% |
Other | 6 | 17% |
Unknown | 10 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 37% |
Biochemistry, Genetics and Molecular Biology | 5 | 14% |
Nursing and Health Professions | 1 | 3% |
Psychology | 1 | 3% |
Agricultural and Biological Sciences | 1 | 3% |
Other | 0 | 0% |
Unknown | 14 | 40% |